Cargando…

In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli

BACKGROUND: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kromann, Sofie, Hvidtfeldt, Anna, Boye, Mette, Sørensen, Dorte Bratbo, Jørgensen, Steffen, Nielsen, Jens Peter, Olsen, Rikke Heidemann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330422/
https://www.ncbi.nlm.nih.gov/pubmed/30634900
http://dx.doi.org/10.1186/s12866-018-1383-5
_version_ 1783386969980534784
author Kromann, Sofie
Hvidtfeldt, Anna
Boye, Mette
Sørensen, Dorte Bratbo
Jørgensen, Steffen
Nielsen, Jens Peter
Olsen, Rikke Heidemann
author_facet Kromann, Sofie
Hvidtfeldt, Anna
Boye, Mette
Sørensen, Dorte Bratbo
Jørgensen, Steffen
Nielsen, Jens Peter
Olsen, Rikke Heidemann
author_sort Kromann, Sofie
collection PubMed
description BACKGROUND: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the potency of sertraline as a tetracycline adjuvant in pigs. METHODS: Forty-eight nursery pigs were divided into four treatment groups: Tetracycline, sertraline, tetracycline/sertraline or un-medicated control. Fecal and ileal samples were obtained before treatment, 48 h and nine days after five days of treatment, respectively. Colony forming units (CFU) of tetracycline resistant coliforms in each sample (ileal or fecal) and CFU of an orally inoculated tetracycline-resistant strain of Escherichia coli were determined at each sampling point. The microbiome of fecal and ileal and samples was analyzed by sequencing of the 16S V3-V4 region. RESULTS: The results did not provide evidence that sertraline in combination with tetracycline has any impact on tetracycline resistant bacteria in either fecal or ileum samples, while in the tetracycline treated group of pigs, an increase in the prevalence of a tetracycline resistant indicator strain of Escherichia coli shortly after ended five-day treatment was observed. The ileal samples obtained shortly after ended treatment showed treatment-associated changes in the composition of the microbiota in the groups of pigs treated with tetracycline (+/−) sertraline. While tetracycline treatment increased the abundance in the reads of E. coli, sertraline/tetracycline treatment led to increased abundances of Streptococcus spp. and decreased abundances of Lactobacillus spp. However, all observed differences (on CFU counts and microbiota composition) between groups shortly after treatment had diminished in less than two weeks after last treatment day. CONCLUSIONS: Sertraline (+/−) tetracycline treatment did not reduce the long-term level of tetracycline-resistant bacteria in the feces or small intestine contents of piglets compared to the un-medicated control group of pigs. The result of this study reflects the importance of in vivo studies for confirmation of the antimicrobial helper-compound potential of an in vitro active compound. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12866-018-1383-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6330422
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63304222019-01-16 In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli Kromann, Sofie Hvidtfeldt, Anna Boye, Mette Sørensen, Dorte Bratbo Jørgensen, Steffen Nielsen, Jens Peter Olsen, Rikke Heidemann BMC Microbiol Research Article BACKGROUND: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the potency of sertraline as a tetracycline adjuvant in pigs. METHODS: Forty-eight nursery pigs were divided into four treatment groups: Tetracycline, sertraline, tetracycline/sertraline or un-medicated control. Fecal and ileal samples were obtained before treatment, 48 h and nine days after five days of treatment, respectively. Colony forming units (CFU) of tetracycline resistant coliforms in each sample (ileal or fecal) and CFU of an orally inoculated tetracycline-resistant strain of Escherichia coli were determined at each sampling point. The microbiome of fecal and ileal and samples was analyzed by sequencing of the 16S V3-V4 region. RESULTS: The results did not provide evidence that sertraline in combination with tetracycline has any impact on tetracycline resistant bacteria in either fecal or ileum samples, while in the tetracycline treated group of pigs, an increase in the prevalence of a tetracycline resistant indicator strain of Escherichia coli shortly after ended five-day treatment was observed. The ileal samples obtained shortly after ended treatment showed treatment-associated changes in the composition of the microbiota in the groups of pigs treated with tetracycline (+/−) sertraline. While tetracycline treatment increased the abundance in the reads of E. coli, sertraline/tetracycline treatment led to increased abundances of Streptococcus spp. and decreased abundances of Lactobacillus spp. However, all observed differences (on CFU counts and microbiota composition) between groups shortly after treatment had diminished in less than two weeks after last treatment day. CONCLUSIONS: Sertraline (+/−) tetracycline treatment did not reduce the long-term level of tetracycline-resistant bacteria in the feces or small intestine contents of piglets compared to the un-medicated control group of pigs. The result of this study reflects the importance of in vivo studies for confirmation of the antimicrobial helper-compound potential of an in vitro active compound. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12866-018-1383-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-11 /pmc/articles/PMC6330422/ /pubmed/30634900 http://dx.doi.org/10.1186/s12866-018-1383-5 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kromann, Sofie
Hvidtfeldt, Anna
Boye, Mette
Sørensen, Dorte Bratbo
Jørgensen, Steffen
Nielsen, Jens Peter
Olsen, Rikke Heidemann
In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title_full In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title_fullStr In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title_full_unstemmed In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title_short In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli
title_sort in vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant escherichia coli
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330422/
https://www.ncbi.nlm.nih.gov/pubmed/30634900
http://dx.doi.org/10.1186/s12866-018-1383-5
work_keys_str_mv AT kromannsofie invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT hvidtfeldtanna invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT boyemette invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT sørensendortebratbo invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT jørgensensteffen invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT nielsenjenspeter invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli
AT olsenrikkeheidemann invitrosynergyofsertralineandtetracyclinecannotbereproducedinpigsorallychallengedwithatetracyclineresistantescherichiacoli